Yet, hyperinsulinemia by increasing the bioavailability of IGF-1 and IGF-2 may favor tumor progression and the activation of IGF-1R, IR/IGF-1R hybrids, IR-A, and their interaction with other molecular partners [79,81,95]. The gene discussed is IGF2; the disease is Hyperinsulinemia.